Change in Preferred Drug List Status for Glucocorticoids, Inhaled Drug Class

Date: May 12, 2025

Attention: Prescribers

Effective date: May 6, 2025

Call to action: Due to the shortage, Health and Human services Commission (HHSC) removed the non-preferred status of the drugs in the table below from the authorized generic (AG) fluticasone HFA products on the preferred drug list (PDL), effective May 6, 2025. 

Background: The manufacturers of brand-name Asmanex HFA, Organon, and QVAR RediHaler, Teva

Pharmaceuticals, reported product backorders due to distribution and manufacturing delays.

How this impacts providers: These changes allow providers to prescribe the AG fluticasone HFA products without requiring a PDL prior authorization and continue access to necessary asthma control medications for members.

Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.

If you have any questions, please email Provider Relations at tchppharmacy@texaschildrens.org. 

For access to all provider alerts: www.texaschildrenshealthplan.org/provideralerts.